Abstract Lymphoma growth and progression may be enhanced by angiogenesis. Both vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) play an important role in this process. The present study aimed to investigate the association of VEGF -936C/T and bFGF -921C/G gene polymorphisms with the clinicopathological characteristics of the studied patients and progression of NHL disease. Patients and methods: Clinico-hematological profiles were done for 50 NHL patients. The genotypes and allelic frequencies of VEGF and bFGF polymorphisms were detected using Polymerase Chain ReactionRestriction Fragment Length Polymorphism (PCR-RFLP). PCR products after adding restriction endonuclease were analyzed using QIAxcel advanced (automated) instrument. Results: there was a trend of significance of VEGF 936-T allele among NHL patients with advanced clinical staging compared to patients with early stages withP value 0.082. As regards the progression of the disease determined by international prognostic index (IPI), it was noticed that there was a borderline significance between VEGF CT genotype and IPI score among patients with intermediate high/high IPI compared to patients with low/intermediate low IPI withP value 0.074. The bFGF 921-G variant was associated frequently with aggressive histological subtype of NHL and showed a borderline significance with NHL patients presented with intermediate high/high IPI score and BM infiltration withP value 0.098 and 0.054 respectively. Conclusion: our results demonstrated that VEGF-936C/T and bFGF-921C/G gene polymorphisms may potentially affect the progression of NHL. Further larger scale studies are needed.